Eli Lilly and Co (NYSE:LLY)
$ 777.77 11.09 (1.45%) Market Cap: 739.20 Bil Enterprise Value: 752.28 Bil PE Ratio: 116.50 PB Ratio: 57.70 GF Score: 81/100

Eli Lilly and Co at Morgan Stanley Healthcare Conference Transcript

Sep 11, 2019 / 05:00PM GMT
Release Date Price: $111.69 (+0.53%)
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst

All right. Good afternoon, everyone. So I'm pleased to welcome one of the executive team members of Eli Lilly, Dan Skovronsky, who is the Head of R&D, effectively. His formal title is Chief Scientific Officer and President of Lilly Research Laboratories. Dan, we're happy to have you here. I do need to refer everyone to a disclaimer at www.morganstanley.com/researchdisclosures.

Just to give you a little bit of a sense for Dan's background. He interestingly has responsibility for Global Business Development at Lilly, which is new for the Head of R&D at Lilly, and I'll ask you talk about that a little bit. And he originally joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals where he had been CEO since founding the company in 2004.

So Dan, you've been Chief Scientific Officer since last summer. I would love to hear a little bit about how you're evolving

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot